Insilico Medicine has moved its AI‑designed TNIK inhibitor, Rentosertib, into a Phase III clinical trial, marking a rare end‑to‑end showcase of generative‑AI drug discovery for idiopathic pulmonary fibrosis (IPF). Insilico Medicine, the Hong Kong‑listed biotech that builds its pipeline on generative‑AI platforms such as Pharma.AI, announced on July 7 that the once‑daily oral molecule Rentosertib will enter... Read More









